A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer
- 211 Downloads
Preclinical studies in small cell lung cancer (SCLC) have shown that hyaluronic acid (HA) can be effectively used to deliver chemotherapy and selectively decrease CD44 expressing (stem cell-like) tumour cells. The current study aimed to replicate these findings and obtain data on safety and activity of HA-irinotecan (HA-IR). Eligible patients with extensive stage SCLC were consented. A safety cohort (n = 5) was treated with HA-IR and Carboplatin (C). Subsequently, the patients were randomised 1:1 to receive experimental (HA-IR + C) or standard (IR + C) treatment, to a maximum of 6 cycles. The second line patients were added to the study and treated with open label HA-IR + C. Tumour response was measured after every 2 cycles. Baseline tumour specimens were stained for CD44s and CD44v6 expression. Circulating tumour cells (CTCs) were enumerated before each treatment cycle. Out of 39 patients screened, 34 were evaluable for the study. The median age was 66 (range 39–83). The overall response rates were 69% and 75% for experimental and standard arms respectively. Median progression free survival was 42 and 28 weeks, respectively (p = 0.892). The treatments were well tolerated. The incidence of grade III/IV diarrhea was more common in the standard arm, while anaemia was more common in the experimental arm. IHC analysis suggested that the patients with CD44s positive tumours may gain survival benefit from HA-IR. HA-IR is well tolerated and active in ES-SCLC. The effect of HA-IR on CD44s + cancer stem-like cells provide an early hint towards a potential novel target.
KeywordsSmall cell lung cancer CD44 Hyaluronic acid Cancer stem cells
The authors thank Peter Midolo and Zdenka Prodanivc for their technical support.
The study was supported by a grant from Alchemia Oncology (Project ACO-003).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Alamgeer M, Ganju V, Kumar B et al. (2014) Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer breast cancer research : BCR 16:R44, doi: https://doi.org/10.1186/bcr3648
- 3.Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical cancer research : an official journal of the American Association for Cancer Research 10:6897–6904. https://doi.org/10.1158/1078-0432.CCR-04-0378 CrossRefGoogle Scholar
- 5.Ardizzoni A, Manegold C, Debruyne C et al (2003) European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 9:143–150Google Scholar
- 10.Chen G, Huynh M, Fehrenbacher L et al (2009) Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27:1401–1404. https://doi.org/10.1200/JCO.2008.20.2127 CrossRefGoogle Scholar
- 13.Dalla Pozza E, Lerda C, Costanzo C et al (2013) Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochim Biophys Acta 1828:1396–1404. https://doi.org/10.1016/j.bbamem.2013.01.020 CrossRefPubMedGoogle Scholar
- 15.Ganesh S, Iyer AK, Morrissey DV, Amiji MM (2013) Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34:3489–3502. https://doi.org/10.1016/j.biomaterials.2013.01.077 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Gibbs P, Clingan PR, Ganju V et al (2011) Hyaluronan-irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother Pharmacol 67:153–163. https://doi.org/10.1007/s00280-010-1303-3 CrossRefPubMedGoogle Scholar
- 18.Han D, Wang G, Sun L, Ren X, Shang W, Xu L, Li S (2017) Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: a meta-analysis. Eur J Cancer Care (Engl) 26. https://doi.org/10.1111/ecc.12723
- 19.Hanna N, Bunn PA, Jr., Langer C et al. (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24:2038–2043 doi: https://doi.org/10.1200/JCO.2005.04.8595
- 24.Lara PN Jr, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535. https://doi.org/10.1200/JCO.2008.20.1061 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Naito T, Tanaka F, Ono A et al (2012) Prognostic impact of circulating tumor cells in patients with small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 7:512–519. https://doi.org/10.1097/JTO.0b013e31823f125d CrossRefGoogle Scholar
- 33.Pan D, Hou M, Li H, Yu P, Liu J (2006) Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: a randomized clinical trial. Zhongguo Fei Ai Za Zhi 9:443–446. https://doi.org/10.3779/j.issn.1009-3419.2006.05.11 PubMedGoogle Scholar
- 36.Ramalingam S, Belani CP, Day R, Zamboni BA, Jacobs SA, Jett JR (2004) Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 15:247–251CrossRefGoogle Scholar
- 39.Roth BJ, Johnson DH, Einhorn LH et al (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the southeastern cancer study group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10:282–291CrossRefGoogle Scholar
- 40.Roudi R, Madjd Z, Korourian A, Mehrazma M, Molanae S, Sabet MN, Shariftabrizi A (2014) Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer biomarkers : section A of Disease markers 14:457–467. https://doi.org/10.3233/CBM-140424 CrossRefPubMedGoogle Scholar
- 42.Schmittel A, Sebastian M, Fischer von Weikersthal L et al (2011) A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22:1798–1804. https://doi.org/10.1093/annonc/mdq652 CrossRefPubMedGoogle Scholar
- 45.Shi Y, Hu Y, Hu X, Li X, Lin L, Han X (2015) Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: a multicenter randomized controlled clinical trial. Thorac Cancer 6:785–791. https://doi.org/10.1111/1759-7714.12303 CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Zatloukal P, Cardenal F, Szczesna A et al (2010) A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 21:1810–1816. https://doi.org/10.1093/annonc/mdq036 CrossRefPubMedGoogle Scholar